Weight Loss Qualifier

Weight Loss Treatment

Semaglutide, a glucagon-like peptide-1 receptor agonist, is approved to treat type 2 diabetes, with subcutaneous injection doses of 0.25, 0.5, and 1 mg administered once weekly and oral doses of 3, 7, and 14 mg administered once daily. In June 2021, the FDA approved subcutaneous semaglutide for long-term weight management, with higher doses of 1.7 and 2.4 mg once weekly. The Semaglutide Treatment Effect in People With Obesity (STEP) trials have shown the efficacy of semaglutide for the treatment of obesity.

In trials, patients receiving semaglutide, 2.4 mg, lost a mean of 6% of their weight by week 12 and 12% of their weight by week 28.

MinuteMD physicians are experienced in semaglutide weight loss protocols and we are ready to help you begin your long term weight loss journey! To get started, we just need you to answer a few questions for your profile below to determine your eligibility. It is important that you answer these questions honestly and to the best of your ability. Upon receipt and enrollment, we’ll order bloodwork for you and you’ll be on your way to your weight loss goals very quickly!


FDA Press Release
Patient Trial Results, Wissam Ghusn, MD1Alan De la Rosa, MD1Daniel Sacoto, MD1; et al